β-synuclein in the pathogenesis of Parkinson's disease and related α-synucleinopathies: Emerging roles and new directions

Future Neurology

Volumn 7, Issue 2, 2012, Pages 155-163

  Hashimoto, Makoto ^a   La Spada, Albert R ^b,c  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

synuclein; synuclein; aggregation; dementia with Lewy bodies; gain of function; loss of function; misfolding protofibrils; Parkinsons disease; synucleinopathy

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN;

BETA SYNUCLEIN GENE; DEGENERATIVE DISEASE; DEMENTIA; GAIN OF FUNCTION MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

EID: 84858192847     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.5     Document Type: Review

References (57)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79(4), 368-376 (2008). (Pubitemid 351441488)
2. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 363(9423), 1783-1793 (2004). (Pubitemid 38698383)
3. Hashimoto M, Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 9(4), 707-720 (1999). (Pubitemid 29470963)
4. Rochet JC, Lansbury PT Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10(1), 60-68 (2000). (Pubitemid 30099328)
5. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5(10), 832-837 (1998). (Pubitemid 28484393)
6. Muzerengi S, Contrafatto D, Chaudhuri KR. Non-motor symptoms: identification and management. Parkinsonism Relat. Disord. 13(Suppl. 3), S450-S456 (2007). (Pubitemid 351215285)
7. Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat. Disord. 16(3), 177-180 (2010).
8. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr. Opin. Neurol. 17(4), 399-404 (2004). (Pubitemid 39071415)
9. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68(11), 812-819 (2007). (Pubitemid 46568532)
10. Lavedan C. The synuclein family. Genome Res. 8(9), 871-880 (1998). (Pubitemid 28495441)
11. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur. J. Biochem. 217(3), 1057-1063 (1993). (Pubitemid 23326889)
12. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 345(1), 27-32 (1994). (Pubitemid 24154659)
13. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35(43), 13709-13715 (1996). (Pubitemid 26363912)
14. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90(23), 11282-11286 (1993). (Pubitemid 23354413)
15. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32(2), 213-223 (2001). (Pubitemid 33030190)
16. Bartels T, Choi JG, Selkoe DJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362), 107-110 (2011).
17. Lavedan C, Buchholtz S, Auburger G, et al. Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. DNA Res. 5(6), 401-402 (1998). (Pubitemid 128670162)
18. Lincoln S, Crook R, Chartier-Harlin MC, et al. No pathogenic mutations in the beta-synuclein gene in Parkinson's disease. Neurosci. Lett. 269(2), 107-109 (1999). (Pubitemid 29335424)
19. Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63(5), 805-811 (2004). (Pubitemid 39297638)
20. Uversky VN, Li J, Souillac P, et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277(14), 11970-11978 (2002). (Pubitemid 34952757)
21. Park JY, Lansbury PT Jr. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 42(13), 3696-3700 (2003). (Pubitemid 36402661)
22. Lee D, Paik SR, Choi KY. Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein. FEBS Lett. 576(1-2), 256-260 (2004). (Pubitemid 39330493)
23. da Costa CA, Masliah E, Checler F. Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. J. Biol. Chem. 278(39), 37330-37335 (2003). (Pubitemid 37175250)
24. Hashimoto M, Bar-On P, Ho G, et al. Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J. Biol. Chem. 279(22), 23622-23629 (2004). (Pubitemid 38685677)
25. Alves da Costa C, Paitel E, Vincent B, Checler F. Alpha-synuclein lowers p53- dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 277(52), 50980-50984 (2002). (Pubitemid 36042267)
26. Thomas B, Mandir AS, West N, et al. Resistance to MPTP-neurotoxicity in alpha-synuclein knockout mice is complemented by human alpha-synuclein and associated with increased beta-synuclein and Akt activation. PLoS ONE 6(1), e16706 (2011).
27. Fan Y, Limprasert P, Murray IV, et al. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum. Mol. Genet. 15(20), 3002-3011 (2006). (Pubitemid 44530704)
28. Wei J, Fujita M, Nakai M, et al. Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies. J. Biol. Chem. 282(39), 28904-28914 (2007). (Pubitemid 47606052)
29. Wei J, Fujita M, Nakai M, et al. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Am. J. Pathol. 174(5), 1891-1909 (2009).
30. Fujita M, Sugama S, Sekiyama K, et al. A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat. Commun. 1, 110 (2010).
31. Rockenstein E, Mallory M, Hashimoto M, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68(5), 568-578 (2002). (Pubitemid 34575622)
32. Iwata A, Miura S, Kanazawa I, Sawada M, Nukina N. Alpha-synuclein forms a complex with transcription factor Elk-1. J. Neurochem. 77(1), 239-252 (2001). (Pubitemid 32245098)
33. Israeli E, Sharon R. Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein. J. Neurochem. 108(2), 465-474 (2009).
34. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914(1-2), 48-56 (2001). (Pubitemid 32905430)
35. Beyer K, Domingo-Sabat M, Santos C, Tolosa E, Ferrer I, Ariza A. The decrease of beta-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain 133(Pt 12), 3724-3733 (2010).
36. Galvin JE, Uryu K, Lee VM, Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl Acad. Sci. USA 96(23), 13450-13455 (1999).
37. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol. 157(2), 361-368 (2000). (Pubitemid 30626903)
38. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688), 1292-1295 (2004). (Pubitemid 39129234)
39. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120(Pt 23), 4081-4091 (2007).
40. Yamin G, Munishkina LA, Karymov MA, Lyubchenko YL, Uversky VN, Fink AL. Forcing nonamyloidogenic beta-synuclein to fibrillate. Biochemistry 44(25), 9096-9107 (2005).
41. Zibaee S, Fraser G, Jakes R, et al. Human beta-synuclein rendered fibrillogenic by designed mutations. J. Biol. Chem. 285(49), 38555-38567 (2010).
42. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4(2), 160-164 (2002).
43. Mbefo MK, Paleologou KE, Boucharaba A, et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285(4), 2807-2822 (2010).
44. Ellis CE, Schwartzberg PL, Grider TL, Fink DW, Nussbaum RL. Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276(6), 3879-3884 (2001).
45. Chen L, Periquet M, Wang X, et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest. 119(11), 3257-3265 (2009).
46. Ia KK, Jeschke GR, Deng Y, et al. Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of beta-synuclein as a potential CHK physiological substrate. Biochemistry 50(31), 6667-6677 (2011).
47. Cole RN, Hart GW. Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem. 79(5), 1080-1089 (2001). (Pubitemid 33117089)
48. Bertoncini CW, Rasia RM, Lamberto GR, et al. Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation. J. Mol. Biol. 372(3), 708-722 (2007). (Pubitemid 47313489)
49. Aghazadeh B, Rosen MK. Ligand recognition by SH3 and WW domains: the role of N-alkylation in PPII helices. Chem. Biol. 6(9), R241-R246 (1999). (Pubitemid 29427373)
50. Syme CD, Blanch EW, Holt C, et al. A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. Eur. J. Biochem. 269(1), 148-156 (2002). (Pubitemid 34107348)
51. Martin JB. CNS genetic disorders: loss of function, gain of function, or something else? Curr. Opin. Neurobiol. 5(5), 669-673 (1995).
52. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol. Neurodegener. 1, 5 (2006).
53. Alves da Costa C, Dunys J, Brau F, Wilk S, Cappai R, Checler F. 6-hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J. Biol. Chem. 281(14), 9824-9831 (2006). (Pubitemid 43864701)
54. Hashimoto M, Rockenstein E, Mante M, et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther. 11(23), 1713-1723 (2004). (Pubitemid 39591766)
55. Lee JA, Lupski JR. Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders. Neuron 52(1), 103-121 (2006). (Pubitemid 44466365)
56. La Spada AR. Getting a handle on Huntington's disease: silencing neurodegeneration. Nat. Med. 15(3), 252-253 (2009).
57. Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides. J. Mol. Neurosci. 19(1-2), 63-69 (2002). (Pubitemid 35021252)